Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: An Updated Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].

Anti-tumour necrosis factor alphas (anti-TNFs) such as infliximab (e.g., Remicade©) are biologics that are proven effective against autoimmune inflammatory diseases. Biologics are large, protein-based agents used to block inflammation for a variety of serious diseases. Infliximab can be used for a variety of chronic inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD), psoriatic arthritis (PA), and plaque psoriasis (PP).– More recently, subsequent entry biosimilar drugs for infliximab have been introduced to the market due to the patent expiry of the originator (or innovator) drug. Biosimilar drugs are therapeutically and biologically similar to originators, appearing in general when exclusivity rights are lost. 'Biosimilar infliximab' is used interchangeably with subsequent entry infliximab in this review.

http://ift.tt/2ui57R5